Mice Model Market
By Type;
Inbred Mice, Outbred Mice, Genetically Engineered Mice, Hybrid/Congenic Mice, Conditioned/Surgically Modified Mice, and Spontaneous Mutant MiceBy Services;
Breeding and RederivationBy Application;
Research and Drug DiscoveryBy Geography;
North America, Europe, Asia Pacific, Middle East & Africa, and Latin America - Report Timeline (2021 - 2031)Mice Model Market Overview
Mice Model Market (USD Million)
Mice Model Market was valued at USD 1,735.45 million in the year 2024. The size of this market is expected to increase to USD 2,828.96 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 7.2%.
Mice Model Market
*Market size in USD million
CAGR 7.2 %
Study Period | 2025 - 2031 |
---|---|
Base Year | 2024 |
CAGR (%) | 7.2 % |
Market Size (2024) | USD 1,735.45 Million |
Market Size (2031) | USD 2,828.96 Million |
Market Concentration | Medium |
Report Pages | 381 |
Major Players
- Charles River Laboratories International, Inc.
- The Jackson Laboratory
- Taconic Biosciences, Inc.
- ENVIGO
- Laboratory Corporation of America Holdings
- Janvier Labs
- Harbour Antibodies Bv (A Subsidiary of Harbour Biomed)
- Trans Genic, Inc.
- Genoway
- Horizon Discovery Group PLC (Sage Labs, Inc.)
- Ingenious Targeting Laboratory
Market Concentration
Consolidated - Market dominated by 1 - 5 major players
Mice Model Market
Fragmented - Highly competitive market without dominant players
The Mice Model Market is experiencing substantial growth due to the increasing reliance on animal models for drug discovery and disease research. Mice models account for over 60% of preclinical testing efforts, driven by their genetic similarity to humans and ease of genetic manipulation. The trend is being amplified by rising investments in biomedical R&D and the development of novel therapeutic areas including oncology and neurology.
Genetic Engineering Advancements
Recent progress in gene-editing technologies like CRISPR has boosted the demand for genetically modified mice, enabling precise disease modeling. This has led to a 35% rise in customized mouse model usage, significantly improving the predictability of treatment outcomes. The increasing sophistication of transgenic and knockout models continues to fuel research adoption rates in academic and pharmaceutical settings.
Application in Personalized Medicine
The growing emphasis on personalized medicine has expanded the role of humanized mice, with adoption growing by over 40% in the past few years. These models are pivotal in replicating patient-specific responses, especially in immunotherapy and rare disease studies. The accuracy and relevance of these models are transforming early-stage validation of treatment approaches.
Regulatory and Ethical Considerations
Despite their advantages, the market faces scrutiny over ethical concerns and evolving regulations, which have prompted a 20% increase in demand for alternatives like in vitro methods. However, mice models remain indispensable due to their proven reliability in mimicking human disease biology, especially in long-term efficacy and toxicity studies.
Technological Integration and Future Outlook
Integration of AI and digital imaging tools in model evaluation is accelerating research timelines and enhancing reproducibility. These innovations have led to a 25% improvement in efficiency and data accuracy, paving the way for a more refined use of mice models. As precision research and AI-driven analytics converge, the market is expected to sustain robust momentum in the coming years.
Mice Model Market Recent Developments
-
In December 2023, Biocytogen signed a global licensing agreement with Neurocrine Biosciences, providing rights to access and utilize select antibodies. The deal supports the development, manufacturing, and commercialization of therapeutic products across all indications, strengthening both firms' positions in the biotechnology sector.
-
In July 2022, GemPharmatech entered a strategic licensing agreement with Charles River Laboratories to distribute its advanced NCG (NOD CRISPR Prkdc Il2r gamma) mouse models across North America. This partnership aims to accelerate biomedical research and enhance preclinical development.
Mice Model Market Segment Analysis
In this report, the Mice Model Market has been segmented by Type, Services, Application, and Geography.
Mice Model Market, Segmentation by Type
The Mice Model Market has been segmented by Type into Inbred Mice, Outbred Mice, Genetically Engineered Mice, Hybrid/Congenic Mice, Conditioned/Surgically Modified Mice and Spontaneous Mutant Mice.
Inbred Mice
Inbred mice account for approximately 35% of the mice model market. These mice are genetically identical, which makes them ideal for reproducible experiments in areas such as cancer research, immunology, and toxicology. The high level of genetic uniformity in inbred mice allows for more accurate and consistent results in biomedical research, especially in drug testing and genetic studies.
Outbred Mice
Outbred mice represent about 25% of the market. These mice are genetically diverse, which makes them valuable in studies that require heterogeneity to reflect the general population. Outbred mice are commonly used in pharmacological testing, immunological studies, and behavioral research, where the natural variability in the population can help predict real-world responses to treatments and conditions.
Genetically Engineered Mice
Genetically engineered mice make up around 20% of the market. These mice are modified to express specific genes, making them indispensable in gene therapy research, drug development, and cancer research. The ability to create mice with human-like diseases or gene mutations is transforming our understanding of disease mechanisms and treatment strategies.
Hybrid/Congenic Mice
Hybrid and congenic mice contribute approximately 10% of the market. These mice are created by crossbreeding different strains to study the inheritance of specific traits or to develop disease models. Hybrid mice are used in genetic research and immunology, as they provide valuable insights into gene-environment interactions and the genetic basis of diseases.
Conditioned/Surgically Modified Mice
Conditioned and surgically modified mice represent about 5% of the market. These mice are specially conditioned or subjected to surgical procedures to model disease states or study specific biological processes. These models are widely used in neurological and cardiovascular research, where the goal is to simulate specific conditions or trauma-induced diseases.
Spontaneous Mutant Mice
Spontaneous mutant mice account for approximately 5% of the mice model market. These mice naturally develop genetic mutations that result in diseases similar to human conditions, making them useful for studying genetic disorders, aging research, and cancer modeling. Their natural mutations provide unique insights into disease progression and potential treatments.
Mice Model Market, Segmentation by Services
The Mice Model Market has been segmented by Services into Breeding, and Rederivation.
Breeding
Breeding accounts for approximately 70% of the mice model market. It plays a crucial role in supplying genetically consistent mice for research purposes. Breeding services are essential in generating mice with specific genetic profiles required for drug testing, genetic research, and disease modeling. The increasing demand for genetically modified mice and the growing focus on reproducible research are key factors driving the growth of this segment.
Rederivation
Rederivation represents about 30% of the market. This process involves the generation of disease-free colonies from existing strains, particularly important for maintaining genetically stable and contaminant-free mice populations. The rise in demand for pathogen-free mice and the need to maintain the health and genetic integrity of animal models are driving the growth of this segment. Rederivation services are widely used in pharmaceutical research, vaccine testing, and preclinical studies.
Mice Model Market, Segmentation by Application
The Mice Model Market has been segmented by Application into Research, and Drug Discovery.
Research
Research accounts for approximately 60% of the mice model market. Mice models are widely used in biomedical research, including genetic studies, disease modeling, and toxicology testing. The high demand for genetically modified mice, particularly for cancer, cardiovascular, and neurodegenerative diseases, continues to drive the growth in the research sector. As the focus on personalized medicine and precision research increases, mice models remain essential in producing reproducible results.
Drug Discovery
Drug discovery makes up around 40% of the market share. Mice models are integral to the early stages of drug development, where they are used to assess the safety and efficacy of new drugs. In the pharmaceutical industry, genetically modified mice play a crucial role in developing targeted therapies for cancer, infectious diseases, and neurological disorders. With the increasing demand for novel drug solutions, mice models are expected to continue supporting drug discovery efforts globally.
Mice Model Market, Segmentation by Geography
In this report, the Mice Model Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.
Regions and Countries Analyzed in this Report
Mice Model Market Share (%), by Geographical Region
North America
North America holds the largest share of the mice model market, accounting for approximately 40%. The United States and Canada are the leading regions due to the advanced research infrastructure and high demand for genetically modified mice in biomedical research, drug discovery, and toxicity testing. As the focus on personalized medicine and genetically engineered mouse models increases, North America continues to drive the growth of the market.
Europe
Europe represents about 30% of the mice model market. Countries such as Germany, the United Kingdom, and France are the main contributors in Europe, with a growing demand for genetically modified mice in oncology, neurological research, and preclinical drug testing. The increasing focus on disease modeling and biomedical research further supports the expansion of the mice model market in this region.
Asia Pacific
Asia Pacific contributes approximately 20% of the market share. The growing healthcare and research sectors in countries like China, India, and Japan are fueling the demand for mice models in drug development, toxicology studies, and genetic research. The increasing adoption of advanced research techniques and the expanding need for affordable animal models are expected to continue driving the growth of the market in the region.
Middle East and Africa
The Middle East and Africa (MEA) region accounts for around 5% of the mice model market. Although the market share remains small, the region is seeing increasing investments in research and development and healthcare infrastructure, particularly in countries like the UAE and Saudi Arabia. The demand for high-quality mice models for drug discovery and disease research is expected to grow steadily in this region.
Latin America
Latin America holds approximately 5% of the market share. The growth in mice model research in countries such as Brazil and Mexico is driven by the increasing demand for biomedical research and pharmaceutical development. With rising awareness of the importance of preclinical testing and the availability of affordable models, the market in Latin America is projected to continue expanding.
Mice Model Market Trends
This report provides an in depth analysis of various factors that impact the dynamics of Mice Model Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.
Comprehensive Market Impact Matrix
This matrix outlines how core market forces—Drivers, Restraints, and Opportunities—affect key business dimensions including Growth, Competition, Customer Behavior, Regulation, and Innovation.
Market Forces ↓ / Impact Areas → | Market Growth Rate | Competitive Landscape | Customer Behavior | Regulatory Influence | Innovation Potential |
---|---|---|---|---|---|
Drivers | High impact (e.g., tech adoption, rising demand) | Encourages new entrants and fosters expansion | Increases usage and enhances demand elasticity | Often aligns with progressive policy trends | Fuels R&D initiatives and product development |
Restraints | Slows growth (e.g., high costs, supply chain issues) | Raises entry barriers and may drive market consolidation | Deters consumption due to friction or low awareness | Introduces compliance hurdles and regulatory risks | Limits innovation appetite and risk tolerance |
Opportunities | Unlocks new segments or untapped geographies | Creates white space for innovation and M&A | Opens new use cases and shifts consumer preferences | Policy shifts may offer strategic advantages | Sparks disruptive innovation and strategic alliances |
Drivers, Restraints and Opportunity Analysis
Drivers
- Increasing biomedical research demand
- Technological advancements enhancing precision
- Growing prevalence of chronic diseases
- Rising focus on personalized medicine
-
Expanded application in drug development - The expanded application of mice models in drug development is a major driver fueling growth in the mice model market. Mice models are widely used to simulate human disease pathways and assess the efficacy and safety of therapeutic compounds before clinical trials. Their genetic similarity to humans, rapid reproduction, and adaptability to genetic modification make them indispensable tools for evaluating drug responses across various disease areas including oncology, neurology, and immunology.
As pharmaceutical companies accelerate research in precision medicine and biologics, the demand for specialized mice models—such as humanized, knockout, and transgenic variants—is rising sharply. These advanced models enable a more accurate representation of human physiological processes, enhancing the predictive value of preclinical studies. This expanded utility in drug discovery and toxicity screening is expected to drive continuous innovation and adoption within the market.
Restraints
- Ethical concerns and regulations
- High costs of maintenance
- Complexities in genetic manipulation
- Limited availability of skilled professionals
-
Variability in experimental outcomes - Variability in experimental outcomes remains a significant restraint in the mice model market, often undermining the reliability and reproducibility of preclinical research. Differences in genetic background, environmental conditions, and handling practices can lead to inconsistent results across laboratories and studies. Such variability challenges the ability to draw definitive conclusions and may delay the drug development process due to the need for additional trials or repeated experiments.
This inconsistency not only increases research costs but also raises concerns about the translational value of animal data to human outcomes. Regulatory bodies and funding agencies are placing greater emphasis on reproducibility, adding pressure on researchers to use highly controlled and standardized mice models. Addressing this challenge requires the adoption of better quality control measures, improved protocol harmonization, and the use of more genetically defined or customized models to ensure consistent and actionable results.
Opportunities
- Emerging economies' adoption
- Development of novel disease models
- Collaborative research initiatives
- Advancements in CRISPR technology
-
Expansion of preclinical studies - The expansion of preclinical studies is opening strong opportunities for the mice model market as pharmaceutical and biotech firms increase R&D activities across therapeutic areas. Mice models are essential tools for evaluating drug safety, efficacy, and disease mechanisms in early-stage research. With rising interest in complex conditions like cancer, neurological disorders, and immunological diseases, the demand for genetically engineered and humanized mice is growing rapidly to support more predictive and reliable study outcomes.
Regulatory expectations for detailed preclinical validation have further extended the role of mice models in drug development pipelines. Advanced models that mimic human disease pathways more accurately are being prioritized to reduce clinical trial failures and improve translational success. As preclinical studies continue to expand globally, suppliers offering customized, high-fidelity mice models stand to gain significantly in this evolving research environment.
Mice Model Market Competitive Landscape Analysis
Key players in Mice Model Market include:
- Charles River Laboratories International, Inc.
- The Jackson Laboratory
- Taconic Biosciences, Inc.
- ENVIGO
- Laboratory Corporation of America Holdings
- Janvier Labs
- Harbour Antibodies Bv (A Subsidiary of Harbour Biomed)
- Trans Genic, Inc.
- Genoway
- Horizon Discovery Group PLC (Sage Labs, Inc.)
- Ingenious Targeting Laboratory
In this report, the profile of each market player provides following information:
- Company Overview and Product Portfolio
- Market Share Analysis
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Introduction
- Research Objectives and Assumptions
- Research Methodology
- Abbreviations
- Market Definition & Study Scope
- Executive Summary
- Market Snapshot, By Type
- Market Snapshot, By Services
- Market Snapshot, By Application
- Market Snapshot, By Region
- Mice Model Market Dynamics
- Drivers, Restraints and Opportunities
- Drivers
- Increasing biomedical research demand
- Technological advancements enhancing precision
- Growing prevalence of chronic diseases
- Rising focus on personalized medicine
- Expanded application in drug development
- Restraints
- Ethical concerns and regulations
- High costs of maintenance
- Complexities in genetic manipulation
- Limited availability of skilled professionals
- Variability in experimental outcomes
- Opportunities
- Emerging economies' adoption
- Development of novel disease models
- Collaborative research initiatives
- Advancements in CRISPR technology
- Expansion of preclinical studies
- Drivers
- PEST Analysis
- Political Analysis
- Economic Analysis
- Social Analysis
- Technological Analysis
- Porter's Analysis
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Threat of New Entrants
- Competitive Rivalry
- Drivers, Restraints and Opportunities
- Market Segmentation
- Mice Model Market, By Type, 2021 - 2031 (USD Million)
- Inbred Mice
- Outbred Mice
- Genetically Engineered Mice
- Hybrid/Congenic Mice
- Conditioned/Surgically Modified Mice
- Spontaneous Mutant Mice
- Mice Model Market, By Services, 2021 - 2031 (USD Million)
- Breeding
- Rederivation
- Mice Model Market, By Application, 2021 - 2031 (USD Million)
- Research
- Drug Discovery
- Mice Model Market, By Geography, 2021 - 2031 (USD Million)
- North America
- United States
- Canada
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Nordic
- Benelux
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia & New Zealand
- South Korea
- ASEAN (Association of South East Asian Countries)
- Rest of Asia Pacific
- Middle East & Africa
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- North America
- Mice Model Market, By Type, 2021 - 2031 (USD Million)
- Competitive Landscape
- Company Profiles
- Charles River Laboratories International, Inc.
- The Jackson Laboratory
- Taconic Biosciences, Inc.
- ENVIGO
- Laboratory Corporation of America Holdings
- Janvier Labs
- Harbour Antibodies Bv (A Subsidiary of Harbour Biomed)
- Trans Genic, Inc.
- Genoway
- Horizon Discovery Group PLC (Sage Labs, Inc.)
- Ingenious Targeting Laboratory
- Company Profiles
- Analyst Views
- Future Outlook of the Market